Effect of ergoline derivative VUFB-6638 on the adenohypophysial prolactin concentration in rats.
The compound VUFB-6638 (N-/D-6-methyl-8-isoergolin-I-yl/N'-N'-diethylurea hydrogen maleinate) was administered for four consecutive days to lactating rats in daily oral doses of 0.1, 1.0 and 2.0 mg/kg. The adenohypophysial prolactin concentration decreased by 34% to 68%, respectively. Moreover, this compound reduced or even completely suppressed the lactation. In view of the assumed relations between prolactin and breast carcinoma, a potential use of the drug is noted.
D000818:Animals; D004873:Ergolines / Q000494:pharmacology*; D005260:Female; D007774:Lactation / Q000187:drug effects; D009929:Organ Size; D010902:Pituitary Gland / Q000378:metabolism*; D010903:Pituitary Gland, Anterior / Q000187:drug effects / Q000378:metabolism*; D011247:Pregnancy; D011388:Prolactin / Q000378:metabolism*; D011389:Prolactin Release-Inhibiting Factors / Q000378:metabolism; D051381:Rats; D014508:Urea / Q000031:analogs & derivatives / Q000494:pharmacology
D004873:Ergolines; D014508:Urea; D011388:Prolactin; D011389:Prolactin Release-Inhibiting Factors